BC013529 Activators
BC013529 activators constitute a chemical class specifically designed to engage and enhance the activity of the biological marker denoted by BC013529. The initial phase in the discovery and characterization of these molecules typically involves a high-throughput screening (HTS) process. This process leverages a vast compendium of diverse chemical entities, screening them against BC013529 to identify compounds that can activate its function. The HTS relies on sensitive and robust assays, often based on detectable signals such as fluorescence or luminescence increases, to indicate the activation of BC013529 in the presence of these compounds. Compounds that demonstrate a significant upregulation of BC013529 activity are marked as hits and progress to the next phase of validation. This subsequent phase includes a battery of secondary assays, which are more target-specific and designed to verify the initial HTS results. The goal in this stage is to ensure that the activation observed is a direct consequence of the interaction between the compound and BC013529, effectively eliminating false positives and focusing on genuine activators.
Once potential activators have been verified, they undergo a detailed analysis to understand their interaction with BC013529. Structural elucidation techniques, such as X-ray crystallography or NMR spectroscopy, may be employed to determine the molecular configuration of the activator when bound to BC013529. These techniques can reveal the intricacies of the interaction at an atomic level, providing crucial insights into how the activator induces an increase in BC013529 activity. Concurrently, biophysical methods such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are used to quantify the activators' binding characteristics, including affinity and kinetics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin binds to its receptor, initiating a signaling cascade that leads to the activation of phosphoinositide 3-kinase (PI3K). PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which recruits AKT1 to the plasma membrane where it is phosphorylated and activated by PDK1 and mTORC2, enhancing its kinase activity involved in glucose metabolism. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
Estrogen binding to its receptor induces a complex signaling network that can activate PI3K, leading to an increase in PIP3 production. This triggers the recruitment and activation of AKT1 at the membrane by PDK1 and mTORC2, strengthening AKT1's function in promoting cell survival and proliferation, particularly in estrogen-responsive tissues. | ||||||
2-Amino-6-chloro-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic Acid Ethyl Ester | 305834-79-1 | sc-479756 | 25 mg | $380.00 | ||
SC79 directly binds to AKT1 and alters its conformation, facilitating its selective membrane localization and phosphorylation by PDK1 and mTORC2, which enhances AKT1 kinase activity involved in survival and metabolism pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate and activate components of the PI3K/AKT1 signaling pathway, thereby indirectly leading to AKT1 activation and increasing its activity in processes such as cell survival, growth, and metabolism. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol activates the sirtuin 1 (SIRT1) deacetylase, which has been shown to deacetylate and positively regulate members of the PI3K/AKT1 pathway. This can result in the activation of AKT1, enhancing its activity in cellular protection and longevity pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator, which can lead to crosstalk with the PI3K/AKT1 signaling cascade, resulting in the indirect activation of AKT1. This enhances AKT1's function in cytoprotection and cell survival. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase 3 (GSK-3), a negative regulator of the PI3K/AKT1 pathway. Inhibition of GSK-3 can relieve its suppression on PI3K/AKT1 signaling, leading to enhanced AKT1 activity involved in neuronal survival and plasticity. | ||||||